[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Careggi Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100407073","extracorporeal-blood-purification-therapy-in-critically-ill-patients-globalarrt-100407073",false,"NCT04580680","Extracorporeal Blood Purification Therapy in Critically Ill Patients (GlobalARRT)","Extracorporeal Blood Purification Therapy in Critically Ill Patients: an Interactive,Web-based,Multicenter,Observational Prospective Registry","GlobalARRT","Inclusion Criteria: patients who meet all the following inclusion criteria may be included in this study:\n\n1. Admission to ICU\n2. Indications for at least one of the following extracorporeal blood purification treatments:\n\n   1. Continuous Renal Replacement Therapy (CRRT) \u002F Intermittent Hemodialysis (IHD) \u002F Hybrid therapies for renal support\u002Freplacement;\n   2. Immunomodulation therapy in critically ill patients using hemodiafilters with larger pore sizes characterized by enhanced transmembrane clearance of larger molecules (such as cytokines), hemodiafilters with enhanced unselective absorption of cytokines and\u002For endotoxins, cartridges with enhanced absorption of cytokines and\u002For endotoxins, techniques aimed at improving extracorporeal removal of cytokines and\u002For endotoxins.\n\nIt should be underlined that the lack of established guidelines on the use of membranes for extracorporeal blood purification (and on RRTs in general) leads to variability in clinical practice and treatments are initiated in accordance with the judgement of the responsible physician. Under these circumstances, it is preferable to keep inclusion criteria as wide as possible so as to obtain a real picture of clinical practice worldwide.\n\nExclusion Criteria: besides contraindications to the use of the EBP adopted (as from the manual of instructions), there are no exclusion criteria.","ALL",{"count":19,"type":20},1000,"ESTIMATED","10 Days","OBSERVATIONAL","Worldwide, the use of Extracorporeal Blood Purification (EBP) in everyday clinical practice is becoming increasingly common, particularly in critical care settings. The efficacy of most of these treatments on removal of inflammatory mediators is the main rationale behind the use of EBP in critically ill patients with multiorgan dysfunction. Nonetheless, there are still some doubts as to the clinical efficacy of bacterial toxins and cytokines removal and many clinical trials aiming at exploring the effect of EBP on long-term outcomes of septic patients have failed to demonstrate consistent results regarding 28 day- or hospital-mortality rates. The primary aim of this observational prospective web-based registry is to define the possible clusters of critically ill patients - treated with extracorporeal blood purification therapies worldwide - who are homogeneous regarding both clinical and treatment characteristics and seem to benefit the most from EBP.",[25,26,27,28],"Critical Illness","Acute Kidney Injury","Sepsis","Systemic Inflammatory Response Syndrome","RECRUITING","2025-02-11",{"date":32,"type":33},"2025-02-12","ACTUAL",{"date":35,"type":33},"2020-11-01",{"date":37,"type":20},"2025-09-30",{"name":39,"class":40},"Careggi Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":52,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":56,"locationsCount":57},"100365052","use-of-ebpt-in-critically-ill-patients-with-aki-andor-multiorgan-failure-100365052","NCT04033224","Use of EBPT in Critically Ill Patients With AKI and\u002For Multiorgan Failure","Use of EBPT in Critically Ill Patients With AKI and\u002For Multiorgan Failure: a Multicenter Prospective Observational Registry","Inclusion Criteria:\n\n* critically ill patients in the ICU\n* one of this EPB therapy:\n* CRRT\u002FIHD\u002FHybrid therapies for support\u002F\u002Freplacement renal function\n* immunomodulation achieved by \"high cut-off membranes\", \"endotoxins and\u002For cytokines adsorbent membranes\" or by high-volume hemofiltration\n\nExclusion Criteria:\n\n* patients treated only by Cytosorb® and\u002For Toraymyxin® therapies",{"count":19,"type":20},"The use of extracorporeal blood purification therapies (EBPT) is becoming increasingly widespread worldwide in everyday clinical practice, particularly in the critical care setting. Nonetheless, most of the clinical trials aimed at exploring the effect of EBPT on patients' long-term outcomes have failed to demonstrate consistent results regarding 28 day- or hospital- mortality rates. The aim of this observational prospective registry is to evaluate if there is a cluster of critically ill patients that mostly benefits from extracorporeal blood purification therapies with different EBPTs.",[25,26,27,28],{"date":32,"type":33},{"date":54,"type":33},"2019-07-16",{"date":37,"type":20},{"name":39,"class":40},15,""]